Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Het Amerikaanse farmabedrijf Novavax zag zijn koers bijna verdrievoudigen en dat was volledig te danken aan sectorgenoot Sanofi. Het Franse farmabedrijf neemt een belang van 5% in Novavax en de waarde ...
, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
The Gaithersburg biotech has lifted its going-concern warning after receiving a cash infusion. Novavax Inc. is getting a big cash infusion after signing a multibillion-dollar deal with French ...
Novavax (NVAX) stock surged after reaching a licensing agreement with Sanofi (SNY) for its COVID-19 vaccine and Matrix-M adjuvant. Read more here.
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.